Alto Pharmacy valuation, funding and investors

Alto Pharmacy works in prescription medication fulfillment services, based in San Francisco, United States. Founded in 2015, it has about 803 employees.

San Francisco Series F

VALUATION · TODAY

$613M −7% after Series F

Range $112M – $825M · Grade C

TODAY

+12 MO

$1.00B

$2.00B

$3.00B

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

2027

Series C $50.0M

Series D $250M

Series E $200M

Series F

ValuationBefore first round12-month outlook: where it points, how wide it fansHover the past: the outlook shows what was predicted then

HEADCOUNT · TODAY803 employees

−1%6m growth

−3%1y growth

−3%2y growth

500

1,000

1,500

Data from Jan 2021

TODAY

Predicted in 1 yr $567M −7% vs today

Predicted next raise $74.4M if a round comes

Winding-down probability 14%

Last round: Series F · Jun 2023
Valuation at last round: $531M
Headcount: 803 · flat
Grade: C
Founded: 2015

How VCMC values companies →

Alto Pharmacy valuation today

VCMC values Alto Pharmacy at $613M today, with a range of $112M to $825M and a grade of C. The valuation starts from its last funding round, a Series F round in Jun 2023.

Valuation by date (147 rows)

Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.

Alto Pharmacy: valuation by date, as the model would have shown it on each date
Date	Valuation	Range	Predicted in 1 yr	Phase	Headcount	Trend	Grade	Winding-down probability
1 Jan 2015	$5.13M	$1.87M – $14.1M	$5.38M (+5%)	before first round	–	unknown	D	0%
1 Feb 2015	$5.15M	$1.88M – $14.2M	$5.40M (+5%)	before first round	–	unknown	D	0%
1 Mar 2015	$5.17M	$1.88M – $14.2M	$5.42M (+5%)	before first round	–	unknown	D	0%
1 Apr 2015	$5.19M	$1.89M – $14.3M	$5.44M (+5%)	before first round	–	unknown	D	0%
1 May 2015	$5.21M	$1.90M – $14.3M	$5.46M (+5%)	before first round	–	unknown	D	0%
1 Jun 2015	$5.23M	$1.90M – $14.4M	$5.48M (+5%)	before first round	–	unknown	D	0%
1 Jul 2015	$5.25M	$1.91M – $14.4M	$5.50M (+5%)	before first round	–	unknown	D	0%
1 Aug 2015	$5.27M	$1.92M – $14.5M	$5.65M (+7%)	before first round	–	unknown	D	0%
1 Sep 2015	$5.29M	$1.93M – $14.5M	$5.80M (+10%)	before first round	–	unknown	D	0%
1 Oct 2015	$5.31M	$1.93M – $14.6M	$5.95M (+12%)	before first round	–	unknown	D	0%
1 Nov 2015	$5.33M	$1.94M – $14.7M	$6.11M (+15%)	before first round	–	unknown	D	0%
1 Dec 2015	$5.36M	$1.95M – $14.7M	$6.27M (+17%)	before first round	–	unknown	D	0%
1 Jan 2016	$5.38M	$1.96M – $14.8M	$6.45M (+20%)	before first round	–	unknown	D	0%
1 Feb 2016	$5.40M	$1.97M – $14.8M	$6.62M (+23%)	before first round	–	unknown	D	0%
1 Mar 2016	$5.42M	$1.97M – $14.9M	$6.79M (+25%)	before first round	–	unknown	D	0%
1 Apr 2016	$5.44M	$1.98M – $14.9M	$6.97M (+28%)	before first round	–	unknown	D	0%
1 May 2016	$5.46M	$1.99M – $15.0M	$7.16M (+31%)	before first round	–	unknown	D	0%
1 Jun 2016	$5.48M	$2.00M – $15.1M	$7.35M (+34%)	before first round	–	unknown	D	0%
1 Jul 2016	$5.50M	$2.00M – $15.1M	$7.54M (+37%)	before first round	–	unknown	D	0%
1 Aug 2016	$5.65M	$2.06M – $15.5M	$7.75M (+37%)	before first round	–	unknown	D	0%
1 Sep 2016	$5.80M	$2.11M – $15.9M	$7.96M (+37%)	before first round	–	unknown	D	0%
1 Oct 2016	$5.96M	$2.17M – $16.4M	$8.17M (+37%)	before first round	–	unknown	D	0%
1 Nov 2016	$6.12M	$2.23M – $16.8M	$8.39M (+37%)	before first round	–	unknown	D	0%
1 Dec 2016	$6.28M	$2.29M – $17.2M	$8.61M (+37%)	before first round	–	unknown	D	0%
1 Jan 2017	$6.45M	$2.35M – $17.7M	$8.84M (+37%)	before first round	–	unknown	D	0%
1 Feb 2017	$6.62M	$2.41M – $18.2M	$9.08M (+37%)	before first round	–	unknown	D	0%
1 Mar 2017	$6.78M	$2.47M – $18.6M	$9.30M (+37%)	before first round	–	unknown	D	0%
1 Apr 2017	$6.97M	$2.54M – $19.1M	$9.55M (+37%)	before first round	–	unknown	D	0%
1 May 2017	$7.15M	$2.60M – $19.6M	$9.80M (+37%)	before first round	–	unknown	D	0%
1 Jun 2017	$7.34M	$2.67M – $20.2M	$10.1M (+37%)	before first round	–	unknown	D	0%
1 Jul 2017	$7.54M	$2.74M – $20.7M	$10.3M (+37%)	before first round	–	unknown	D	0%
1 Aug 2017	$7.74M	$2.82M – $21.3M	$10.6M (+37%)	before first round	–	unknown	D	0%
1 Sep 2017	$7.95M	$2.89M – $21.8M	$10.9M (+37%)	before first round	–	unknown	D	0%
1 Oct 2017	$8.16M	$2.97M – $22.4M	$11.2M (+37%)	before first round	–	unknown	D	0%
1 Nov 2017	$8.38M	$3.05M – $23.0M	$11.5M (+37%)	before first round	–	unknown	D	0%
1 Dec 2017	$8.60M	$3.13M – $23.6M	$11.8M (+37%)	before first round	–	unknown	D	0%
1 Jan 2018	$8.84M	$3.22M – $24.3M	$12.1M (+37%)	before first round	–	unknown	D	0%
1 Feb 2018	$9.08M	$3.30M – $24.9M	$12.4M (+37%)	before first round	–	unknown	D	0%
1 Mar 2018	$9.30M	$3.39M – $25.5M	$12.7M (+37%)	before first round	–	unknown	D	0%
1 Apr 2018	$9.55M	$3.48M – $26.2M	$13.1M (+37%)	before first round	–	unknown	D	0%
1 May 2018	$9.80M	$3.57M – $26.9M	$13.4M (+37%)	before first round	–	unknown	D	0%
1 Jun 2018	$10.1M	$3.67M – $27.7M	$13.8M (+37%)	before first round	–	unknown	D	0%
1 Jul 2018	$10.3M	$3.76M – $28.4M	$14.2M (+37%)	before first round	–	unknown	D	0%
1 Aug 2018	$10.6M	$3.86M – $29.2M	$14.3M (+35%)	before first round	–	unknown	D	0%
1 Sep 2018	$10.9M	$3.97M – $29.9M	$14.4M (+32%)	before first round	–	unknown	D	0%
1 Oct 2018	$11.2M	$4.07M – $30.7M	$14.6M (+30%)	before first round	–	unknown	D	0%
1 Nov 2018	$11.5M	$4.18M – $31.6M	$14.7M (+28%)	before first round	–	unknown	D	0%
1 Dec 2018	$11.8M	$4.29M – $32.4M	$14.8M (+26%)	before first round	–	unknown	D	0%
6 Dec 2018	$455M	$299M – $899M	$591M (+30%)	after a round	–	unknown	B	0%
1 Jan 2019	$463M	$299M – $899M	$591M (+28%)	after a round	–	unknown	B	0%
1 Feb 2019	$474M	$299M – $899M	$591M (+25%)	after a round	–	unknown	B	0%
1 Mar 2019	$484M	$299M – $899M	$591M (+22%)	after a round	–	unknown	B	0%
1 Apr 2019	$494M	$299M – $899M	$591M (+20%)	after a round	–	unknown	B	0%
1 May 2019	$505M	$299M – $899M	$591M (+17%)	after a round	–	unknown	B	0%
1 Jun 2019	$517M	$299M – $899M	$591M (+14%)	after a round	–	unknown	B	0%
1 Jul 2019	$528M	$299M – $899M	$591M (+12%)	after a round	–	unknown	B	0%
1 Aug 2019	$540M	$299M – $899M	$591M (+9%)	after a round	–	unknown	B	0%
1 Sep 2019	$552M	$299M – $899M	$591M (+7%)	after a round	–	unknown	B	0%
1 Oct 2019	$564M	$299M – $899M	$591M (+5%)	after a round	–	unknown	B	0%
1 Nov 2019	$577M	$299M – $899M	$591M (+2%)	after a round	–	unknown	B	0%
1 Dec 2019	$589M	$299M – $899M	$591M (0%)	after a round	–	unknown	B	0%
1 Jan 2020	$591M	$287M – $899M	$591M (0%)	after a round	–	unknown	B	0%
31 Jan 2020	$701M	$609M – $1.0B	$910M (+30%)	after a round	–	unknown	A	0%
1 Feb 2020	$701M	$609M – $1.0B	$910M (+30%)	after a round	–	unknown	A	0%
1 Mar 2020	$716M	$609M – $1.0B	$910M (+27%)	after a round	–	unknown	A	0%
1 Apr 2020	$732M	$609M – $1.0B	$910M (+24%)	after a round	–	unknown	A	0%
1 May 2020	$748M	$609M – $1.0B	$910M (+22%)	after a round	–	unknown	A	0%
1 Jun 2020	$765M	$609M – $1.0B	$910M (+19%)	after a round	–	unknown	A	0%
1 Jul 2020	$781M	$609M – $1.0B	$910M (+16%)	after a round	–	unknown	A	0%
1 Aug 2020	$799M	$609M – $1.0B	$910M (+14%)	after a round	–	unknown	A	0%
1 Sep 2020	$817M	$609M – $1.0B	$910M (+11%)	after a round	–	unknown	A	0%
1 Oct 2020	$835M	$609M – $1.0B	$910M (+9%)	after a round	–	unknown	A	0%
1 Nov 2020	$853M	$609M – $1.0B	$910M (+7%)	after a round	–	unknown	A	0%
1 Dec 2020	$872M	$609M – $1.0B	$910M (+4%)	after a round	–	unknown	A	0%
1 Jan 2021	$892M	$609M – $1.0B	$910M (+2%)	after a round	490	unknown	A	0%
1 Feb 2021	$910M	$606M – $1.0B	$910M (0%)	after a round	490	unknown	A	0%
1 Mar 2021	$910M	$581M – $1.0B	$910M (0%)	after a round	490	unknown	A	0%
1 Apr 2021	$910M	$555M – $1.0B	$910M (0%)	after a round	490	unknown	B	0%
1 May 2021	$910M	$530M – $1.0B	$910M (0%)	after a round	490	unknown	B	0%
1 Jun 2021	$910M	$506M – $1.0B	$910M (0%)	after a round	490	unknown	B	0%
1 Jul 2021	$910M	$484M – $1.0B	$910M (0%)	after a round	490	unknown	B	0%
1 Aug 2021	$910M	$462M – $1.0B	$910M (0%)	after a round	490	unknown	B	0%
1 Sep 2021	$910M	$441M – $1.0B	$910M (0%)	after a round	490	unknown	B	0%
1 Oct 2021	$910M	$422M – $1.0B	$910M (0%)	after a round	490	unknown	B	0%
1 Nov 2021	$910M	$403M – $1.0B	$910M (0%)	after a round	490	unknown	B	0%
1 Dec 2021	$910M	$385M – $1.0B	$910M (0%)	after a round	490	unknown	B	0%
1 Jan 2022	$910M	$368M – $1.0B	$910M (0%)	after a round	490	unknown	B	0%
28 Jan 2022	$1.7B	$1.5B – $2.5B	$2.2B (+30%)	after a round	490	unknown	A	0%
1 Feb 2022	$1.7B	$1.5B – $2.5B	$2.2B (+30%)	after a round	490	unknown	A	0%
1 Mar 2022	$1.7B	$1.5B – $2.5B	$2.2B (+27%)	after a round	910	growing	A	0%
1 Apr 2022	$1.8B	$1.5B – $2.5B	$2.2B (+24%)	after a round	910	growing	A	0%
1 May 2022	$1.8B	$1.5B – $2.5B	$2.2B (+22%)	after a round	910	growing	A	0%
1 Jun 2022	$1.9B	$1.5B – $2.5B	$2.2B (+19%)	after a round	910	growing	A	0%
1 Jul 2022	$1.9B	$1.5B – $2.5B	$2.2B (+16%)	after a round	910	growing	A	0%
1 Aug 2022	$1.9B	$1.5B – $2.5B	$2.2B (+14%)	after a round	910	unknown	A	0%
1 Sep 2022	$2.0B	$1.5B – $2.5B	$2.2B (+11%)	after a round	910	unknown	A	0%
1 Oct 2022	$2.0B	$1.5B – $2.5B	$2.2B (+9%)	after a round	910	unknown	A	0%
1 Nov 2022	$2.1B	$1.5B – $2.5B	$2.2B (+6%)	after a round	910	unknown	A	0%
1 Dec 2022	$2.1B	$1.5B – $2.5B	$2.2B (+4%)	after a round	910	unknown	A	0%
1 Jan 2023	$2.2B	$1.5B – $2.5B	$2.2B (+2%)	after a round	910	unknown	A	0%
1 Feb 2023	$2.2B	$1.5B – $2.5B	$2.2B (0%)	after a round	910	unknown	A	0%
1 Mar 2023	$2.2B	$1.4B – $2.5B	$2.2B (0%)	after a round	910	unknown	A	0%
1 Apr 2023	$2.2B	$1.3B – $2.5B	$2.2B (0%)	after a round	910	unknown	B	0%
1 May 2023	$2.2B	$1.3B – $2.5B	$2.2B (0%)	after a round	910	unknown	B	0%
1 Jun 2023	$2.1B	$1.2B – $2.4B	$2.0B (-5%)	after a round	880	flat	B	17%
27 Jun 2023	$531M	$462M – $760M	$661M (+24%)	after a round	880	flat	A	17%
1 Jul 2023	$533M	$462M – $760M	$660M (+24%)	after a round	880	flat	A	17%
1 Aug 2023	$543M	$462M – $760M	$658M (+21%)	after a round	880	flat	A	17%
1 Sep 2023	$553M	$462M – $763M	$658M (+19%)	after a round	880	unknown	A	15%
1 Oct 2023	$564M	$462M – $765M	$659M (+17%)	after a round	880	unknown	A	14%
1 Nov 2023	$576M	$462M – $771M	$662M (+15%)	after a round	900	flat	A	13%
1 Dec 2023	$588M	$462M – $773M	$663M (+13%)	after a round	900	flat	A	12%
1 Jan 2024	$601M	$462M – $775M	$664M (+11%)	after a round	900	flat	A	11%
1 Feb 2024	$614M	$462M – $777M	$665M (+8%)	after a round	900	flat	A	10%
1 Mar 2024	$626M	$462M – $778M	$666M (+6%)	after a round	900	flat	A	9%
1 Apr 2024	$639M	$462M – $778M	$665M (+4%)	after a round	890	flat	A	9%
1 May 2024	$653M	$462M – $779M	$666M (+2%)	after a round	890	flat	A	8%
1 Jun 2024	$668M	$462M – $781M	$667M (0%)	after a round	890	flat	A	7%
1 Jul 2024	$680M	$458M – $782M	$666M (-2%)	after a round	890	flat	A	7%
1 Aug 2024	$680M	$437M – $784M	$667M (-2%)	after a round	890	flat	A	6%
1 Sep 2024	$633M	$415M – $741M	$585M (-8%)	after a round	830	flat	A	25%
1 Oct 2024	$629M	$396M – $743M	$582M (-8%)	after a round	830	flat	B	25%
1 Nov 2024	$626M	$377M – $745M	$578M (-8%)	after a round	830	flat	B	25%
1 Dec 2024	$555M	$357M – $701M	$464M (-16%)	after a round	820	flat	B	55%
1 Jan 2025	$548M	$339M – $705M	$458M (-16%)	after a round	820	flat	B	55%
1 Feb 2025	$541M	$323M – $709M	$451M (-16%)	after a round	820	flat	B	55%
1 Mar 2025	$534M	$309M – $713M	$446M (-17%)	after a round	820	flat	B	55%
1 Apr 2025	$527M	$293M – $716M	$440M (-17%)	after a round	820	flat	B	55%
1 May 2025	$532M	$280M – $725M	$449M (-15%)	after a round	820	flat	B	51%
1 Jun 2025	$527M	$266M – $729M	$446M (-15%)	after a round	820	flat	B	50%
1 Jul 2025	$512M	$247M – $733M	$417M (-19%)	after a round	820	flat	B	50%
1 Aug 2025	$518M	$235M – $742M	$426M (-18%)	after a round	826	flat	B	46%
1 Sep 2025	$525M	$224M – $750M	$434M (-17%)	after a round	832	flat	C	42%
1 Oct 2025	$531M	$213M – $755M	$441M (-17%)	after a round	832	flat	C	39%
1 Nov 2025	$537M	$203M – $761M	$448M (-17%)	after a round	832	flat	C	36%
1 Dec 2025	$543M	$193M – $765M	$455M (-16%)	after a round	832	flat	C	33%
1 Jan 2026	$545M	$182M – $765M	$458M (-16%)	after a round	809	flat	C	30%
1 Feb 2026	$551M	$173M – $768M	$463M (-16%)	after a round	809	flat	C	28%
1 Mar 2026	$557M	$165M – $771M	$469M (-16%)	after a round	809	flat	C	26%
1 Apr 2026	$562M	$157M – $774M	$473M (-16%)	after a round	809	flat	C	24%
1 May 2026	$568M	$150M – $776M	$477M (-16%)	after a round	809	flat	C	22%
1 Jun 2026	$573M	$142M – $779M	$482M (-16%)	after a round	812	flat	C	20%
1 Jul 2026	$566M	$135M – $779M	$478M (-16%)	after a round	812	flat	C	18%
1 Aug 2026	$567M	$129M – $773M	$481M (-15%)	after a round	810	flat	C	17%
1 Sep 2026	$567M	$122M – $768M	$484M (-15%)	after a round	810	flat	C	16%
1 Oct 2026	$567M	$116M – $761M	$486M (-14%)	after a round	803	flat	C	14%
24 Oct 2026	$613M	$112M – $825M	$567M (-7%)	after a round	803	flat	C	14%

Key facts about Alto Pharmacy

Founded: 2015
Headquarters: San Francisco, United States
Employees: about 803 -3% in a year
Total raised: $515M
Funding rounds: 5
Last round: Series F Jun 2023

Alto Pharmacy was founded in 2015 by Jamie Karraker and Mattieu Gamache-Asselin.

Alto Pharmacy funding history

Alto Pharmacy has 5 funding rounds on record, from Dec 2018 to Jun 2023, $515M in total. The latest disclosed valuation is $531M post-money (Series F, Jun 2023).

Series F 26 Jun 2023
Investors not disclosed.
Amount undisclosed
$531M post-money, below the round before
Series E 27 Jan 2022
Led by SoftBank Vision Fund, SoftBank; with Madryn Asset Management, Sand Hill Angels, Flucas Ventures, What If Ventures, The Ultima Ventures.
Sources: alto.com
$200M
$1.70B post-money
Series D 30 Jan 2020
Led by SoftBank Vision Fund; with Greenoaks, Jackson Square Ventures, Olive Tree Capital, Zola Global.
Sources: mobihealthnews.com, alto.com, cnbc.com and 1 more
$250M
$700M post-money
Other 17 Jan 2019no round page
With ROAD VENTURES, Frog Ventures.
Sources: dallasinnovates.com
$15M
Series C 5 Dec 2018
Investors not disclosed.
Sources: prweb.com, finsmes.com, pulse2.com and 1 more
$50M

Alto Pharmacy investors

13 investors have backed Alto Pharmacy; SoftBank Vision Fund and SoftBank led at least one round.

SoftBank Vision Fund lead, 2 rounds
SoftBank lead
Flucas Ventures
Greenoaks
The Ultima Ventures
Zola Global

What Alto Pharmacy does

Alto Pharmacy works in drug stores & pharmacies, with 14 recorded offerings and customers in healthcare.

Alto Pharmacy LLC is an American pharmacy company that operates as a specialty pharmacy and provides pharmacy services to patients, providers, insurers, and manufacturers. The company offers prescription fulfillment, medication bundling, and direct access to care specialists, and utilizes digital platforms and technology to support prescription management and medication delivery. Alto Pharmacy is licensed and adheres to privacy and security standards.

Description from Veridion's company data.

Products and services

Prescription Medication Fulfillment Services
Specialty Pharmacy Services
Medication Delivery Services
Fertility Medication Home Delivery
Medication Bundling Services
Treatment Reminder Services
Care Specialist Access Services
Mobile Pharmacy Management Tools Development
Online Account Management Tools Development
AI-Driven Pharmacy Solutions Development
Machine Learning Pharmacy Solutions Development
Patient Cost Transparency Solutions
Pharmacy Platform Innovation Services
Provider and Partner Solutions Development

Markets

Healthcare

Technology

AI and Machine Learning for Operational Efficiency

Certifications

HIPAA compliant
CCPA compliant

Business model

Business-to-Business
Business-to-Consumer
Service Provider
Retail

Industry codes (NAICS)

456110 Pharmacies and Drug Retailers 100% match

Questions about Alto Pharmacy

What is Alto Pharmacy worth?

Valuation $613M (range $112M to $825M), as of 24 Oct 2026. The last disclosed valuation was $531M (Series F, Jun 2023).

Has Alto Pharmacy raised money?

Alto Pharmacy has 5 funding rounds on record, from Dec 2018 to Jun 2023, $515M in total. The latest disclosed valuation is $531M post-money (Series F, Jun 2023).

Who has invested in Alto Pharmacy?

SoftBank Vision Fund, SoftBank, Flucas Ventures, Frog Ventures, Greenoaks and Jackson Square Ventures, and 7 more. Lead investors include SoftBank Vision Fund and SoftBank.

How many people work at Alto Pharmacy?

About 803, down 3% over the last year. Headcount rose from 490 in Jan 2021 to 910 in Feb 2022, then fell to 803 in Sep 2026.

What does Alto Pharmacy do?

Alto Pharmacy works in drug stores & pharmacies, with 14 recorded offerings and customers in healthcare. Its main offerings are prescription medication fulfillment services, specialty pharmacy services and medication delivery services.

When was Alto Pharmacy founded, and where is it based?

Alto Pharmacy was founded in 2015 and is based in San Francisco, United States. It has about 803 employees, down 3% over the last year.

How we value companies Report an issue